US-based EyePoint Pharmaceuticals has engaged Gorman Richardson Lewis Architects (GRLA) to design a new 40,000 sqft lab building located in Northbridge, Massachusetts.
The new building will allow EyePoint to meet US FDA and European Medicines Agency (EMA) standards for producing therapeutics.
EyePoint Pharmaceuticals (EyePoint) develops solutions and technologies to help people facing serious eye disorders. EyePoint Pharmaceuticals brings hope to people with serious eye disease by developing new treatments and drug-delivery systems for many challenging conditions, including macular degeneration, the leading cause of vision loss among adults.
To assist EyePoint with the cGMP manufacturing facility, GRLA is working closely with construction manager RP Masiello and process engineers RemTech and Phoenix Engineering to create a state-of-the-art facility to expand their lab and manufacturing space.
The new building will include clean manufacturing space, support and research labs, warehouse space and office areas and construction is slated to start mid-summer and be completed by mid-2024.
EyePoint’s new facility will be customised for its specific development and manufacturing programmes. It will include 10 production suites for clinical supply and commercial scale manufacturing of approved products, plus laboratory support space, all built to ISO Class 7 cleanroom standards.
The facility will also accommodate Quality Control and Quality Assurance (QC/QA) functions and administrative spaces to support continue growth of their global business.
